Authors: R. Honzák; H. Kurzová Authors‘ workplace: Ústav všeobecného lékařství 1. LF UK, Praha, přednostka MUDr. H. Kurzová Published in: Prakt. Lék. 2001; (7): 391-396 Category:
The authors inform readers on the pharmacological and clinical profile of a new anxiolytic onthe market. Buspiron is indicated in anxious disorders in particular in generalized anxietydisorder. Buspiron has a clinical effect similar to that of currently used benzodiazepineanxiolytics. Contrary to them it has several advantages: it does not affect psychomotorfunctions, does not cause sedation, does not potentiate substances which evoke central depression (alcohol, benzodiazepines and some other psychopharmaceutical preparations), it does notcause habituation, it has a minimumof drug interactions and is well tolerated. Its disadvantageis the late onset of the anxiolytic effect which develops after two weeks or later.
Key words: buspiron - anxiety disorders - anxiolytics - benzodiazepines.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
